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Abstract
Etonogestrel (ENG) implant is an effective method of 
contraception. The implant is designed to provide 
contraceptive efficacy for three years with a relatively quick 
return of fertility upon its removal. Dysfunctional uterine 
bleeding (DUB) is a common side effect of long acting 
progestins and is often the reason patients state for removal 
or discontinuation. A retrospective chart analysis was 
completed on 292 patients who chose to be on the ENG 
implant. Age of patients ranged from 10-29 years of age 
with the average age at implant being 17 years +/- 3 years. 
Patients retained implant for 1-68 months with the average 
use being 21.0 months +/- 15.5 months. Over the 69 month 
period, 158 patients had the complaint of DUB (54.1%) and 
46 patients with DUB had their implants removed because 
DUB was unresolved upon treatment and/or follow up 
(15.6%). Therefore, is it import for clinicians to be aware of 
the likelihood of DUB with implant usage and for them to 
be able to provide appropriate pre and post insertion 
counseling and treatment to all of their patients.  
Keywords: Dysfunctional uterine bleeding, etonogestrel, 
adolescent contraception, abnormal uterine bleeding, 
subdermal contraceptive implant 
Introduction
There are more than 20 million women worldwide 
who use long acting progesterone-only contraceptives 
(1, 2). Implanon™ and its radiopaque version, 
Nexplanon™, are Etonogestrel (ENG) implantable 
rods that are placed subdermally. These implants offer 
effective long term contraception for up to three years 
with a failure rate of only 0.3-1.0% annually. The 
implant is off-white, non-biodegradable rod of 4 cm 
in length with a diameter of 2 mm. Each implant 
contains 68 mg ENG and barium sulfate added to the 
Nexplanon™ version to allow for it to be radiopaque 
(3, 4). ENG prevents pregnancy by not just one but 
three mechanisms; (i) suppresses luteinizing hormone 
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surge and partially suppresses follicle stimulating 
hormone (ii) increases viscosity of the cervical mucus 
that to impede penetration by sperm (iii) thins the 
endometrium to make implantation unlikely (3, 5, 6).  
Studies show that ENG release from these 
implants is slow, steady, and gradually decreases over 
the 3 years of usage. One study showed that ENG 
releases 60 to 70 ug in the first day of implant, 
ensuring therapeutic levels are reached within the first 
few days after implant. After the initial surge of ENG 
release the rate decreases slightly to 40-45 μg/day 
with a gradual decline to 25-30 μg/day at the end of 
three years (5). This makes the 68 mg starting dosage 
more than adequate to prevent pregnancy over the 
three year duration of usage. Also of note is the quick 
return to fertility following implant removal. Unlike 
other long acting contraceptives, patients saw return 
of fertility 1-2 weeks post ENG implant removal (5). 
If used for the duration of the 3 years the ENG 
implant is also very cost effective, and cheaper than 
oral contraceptive pills as well as other hormonal 
methods. 
Despite the many appeals of the ENG implants 
they are not without risks and unwanted side effects. 
The number one reason cited for removal of the 
implant is the troublesome side effect of dysfunctional 
uterine bleed (DUB). A review of data from the 
eleven clinical trials with Implanon™ found that 
11.3% of users discontinued use due to bleeding 
irregularities, mainly frequent or prolonged irregular 
bleeding (3). Bleeding patterns vary from 
amenorrhea, to spotting, to prolonged heavy bleeding 
while on ENG implants (3, 4). 
There are multiple causes of DUB. Causes 
include altered endometrial matrix metalloproteinase 
(MMP), irregular endometrial blood vessels, 
increased vascular fragility, decreased glandular and 
stromal support, and decreased epithelium integrity 
(5-7). A variety of treatments target these different 
mechanisms, with some treatments being more 
effective than others. Most common treatments 
include: Doxycycline, Mifepristone, Combination 
Oral Contraceptive, or NSAIDs. However, it should 
be noted that although these treatments may resolve a 
current episode of DUB, there has been no data to 
show long term improvement in subsequent bleeding 
patterns (1). 
In Implanon™ users, the bleeding pattern is most 
likely to vary within the first three months post 
implant (5, 6). This can lead to frustration especially 
in an adolescent population which is so often more 
focused on the here and now than 3 months in the 
future. Since treatment is not always effective, it is 
important to discuss removal on a case by case basis. 
In supporting women’s contraception needs it is 
important to remember and accept that all women 
have different levels of toleration for DUB and other 
side effects. Some women simply cannot tolerate the 
implant and encouraging retention without dealing 
with the distressing side effects may be 
counterproductive (8). This article focus is on DUB in 
adolescent ENG implant users, the treatment and 
counseling provided for DUB, and how treatment or 
lack of treatment contributed to the desire for implant 
removal in our patient population. 
Methods
We conducted a chart review of the patients who 
received the ENG implant in our adolescent clinic. An 
analysis was completed based on symptoms 
experienced by patients who were on ENG implant 
and their management, which in some cases resulted 
in its removal. Patients who received implants on or 
after February of 2008 were included in this study 
(n=292). DUB was classified by amount of time and 
heaviness of flow and assigned a number 1-5 (see 
table 1). Any patient who was not amenorrheic was 
ultimately classified as a patient with DUB. 
Table 1. Classifying Dysfunctional Uterine Bleed 
1 Amenorrhea 
2 Spotting for <7 days/month 
3 Spotting for >7 days/ month 
4 Heavy bleeding for <7 days per month 
5 Heavy bleeding for >7 days per month 
Results
From February 2008 to November 2013 a total of 292 
patients had either Implanon™ or Nexplanon™ 
placed by a certified and trained clinician in the 
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Division of Adolescent Medicine, University of 
Kentucky, Lexington, KY, USA. The patient 
demographics of this clinic are summarized in table 2.  
We also looked at other high risk behaviors such 
as whether or not patients were sexually active at time 
of implant placement (see table 3). This data is 
relevant as prevention of unwanted pregnancy is 
especially important in patients with co morbid 
conditions such as substance abuse and sexually 
transmitted infections that could cause harm to an 
early developing fetus. 
Table 2. Demographics of implant users at University of Kentucky Adolescent Clinic 
Age at Placement Race Insurance Occupation 
Mean 17 years old White 52.7% Private 70.9% Student 83.9% 
SD 3 years Black 45.2% Medicaid 29.1% Employed 11.0% 
Range 10-29 y/o Hispanic 1.4%   Unemployed 4.8% 
  Other 0.7%     
Table 3. High risk behaviors associated with implant users at University of Kentucky Adolescent Clinic  
at time of placement 
Sexually Active Smoking Status Substance Abuse Age of First Intercourse Prior STDs 
Yes 67.8% Current 22.6% Current 22.6% Average 14.5 Yes 28.1% 
No 30.1% Prior 9.6% Prior 9.6% SD 2.1 No 66.8% 
Unknown 2.1% Never 64.7% Never 22.6% Range 10-21 years Unknown 5.1% 
  Unknown 3.1% Unknown 4.5%     
The age range of patients receiving implant was 
between 10 and 29 years. The number of months the 
patient retained their implant post insertion ranged 
from 0 month (26 days) to 69 months, average 21.0 
months +/-15.5 months before they were electively 
removed. 
DUB was classified on a scale from 1-5 (see table 
1) and was managed in a variety of ways depending 
on patient and classification of DUB. Treatment was 
left up to the clinician’s discretion. As seen in table 4, 
the most common treatment was combined oral 
contraceptive pills alone (31.5% of patients with 
DUB). Resolution of DUB was also variable, which 
helps to emphasize the importance of careful follow 
up and continued counseling post treatment of DUB.  
Table 4. Treatment of patients with DUB 
 % Treated % Resolution with Treatment 
OCPs and Follow Up 31.5% 66.3% 
Naproxen Only 1.4% 75.0% 
OCPs and Naproxen  2.4% 85.7% 
Reassurance and Follow Up  13.0% 86.8% 
No Treatment or Refused Treatment 6.5% 56.2% 
In our experience 54.1% of patients experienced some 
level of DUB (158 out of 292). Also noteworthy is 
that 65.2% of patients inciting DUB were treated with 
some sort of pharmacological method (OCPS, 
Naproxen, or Both), while 13.0% seen in clinic 
received only reassurance and follow up. Over the 69 
months of this study, 86 of 292 patients had their 
implants removed. Although DUB was the 
overwhelming reason for removal in our patient 
population, table 5 depicts other reasons why the 
device was removed. Of interest is that 5.8% of all 
patients, and 17.9% of all patients presenting for 
implant removal, chose to get a new ENG implant 
placed upon expiration of their old implant, 
suggesting these patients were pleased with this form 
of contraception. 
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Table 5. Reasons for implant removal 
Dysfunctional Uterine Bleed 15.8% 
Implant Expired, New Implant Placed 5.8% 
Implant Expired, Patient Switched to Another Form of Birth Control 2.7% 
Other* Reason Stated for Removal 5.1% 
Implant Has Not Been Removed 70.5% 
* “Other” reasons for removal included; cramping, weight gain, pain at implant site, mood disturbances, and patient desiring 
pregnancy. 
In the end 46 of 158 patients citing DUB opted 
for removal of the implant (29.1% DUB patients and 
15.8% of all patients receiving ENG implant). Of 
these 46 patients, the average time of implant usage 
was 16 months +/- 11 months. In comparison to a 
prior smaller scale study done at our institution 
looking at ENG implant and DUB, 15 of 58 patients 
(22.4%) opted for removal because of DUB, with a 
mean usage of 10.9 months. This would suggest that 
our clinicians are doing a better job of counseling and 
treating patients with DUB due to ENG implant use, 
and stresses the importance of clinicians being 
informed and competent at informing patients about 
side effects of ENG implant usage.  
Discussion
Long acting progesterone contraceptive are extremely 
effective in preventing teen pregnancies, which is 
why it is often a contraceptive method of choice for 
patients in our Adolescent Medicine Clinic, especially 
those patients participating in high risk behaviors. 
However, DUB is one of the major reasons for the 
discontinuation and removal of the implant. There are 
patient specific recommendations to manage DUB 
which include: doxycycline, EE, mifepristone, 
combination oral contraceptives, and NSAIDs. Of 
these treatments none are guaranteed to resolve DUB 
or prevent future DUB. Therefore, it is crucial for 
clinicians to provide the patient with adequate pre and 
post insertion counseling, as well as adequate pre-
removal counseling so that patients can have 
reasonable expectations of what side effects could 
occur with implant usage. Also due to the quick return 
to fertility upon implant removal, it is equally 
important to provide post removal recommendations 
for alternative contraceptive methods to prevent 
unintended pregnancy, especially in high risk 
adolescent populations. This study shows high 
prevalence of discontinuation of the method, because 
of bleeding. However, in adolescent population at 
high risk of unwanted pregnancy, it is still an 
effective, long acting method that should continue to 
be utilized with proper counseling and follow up. 
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